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Ablation Therapy of Atrial Fibrillation
Clinical Outcomes of Catheter Substrate
Ablation for High-Risk Patients With Atrial Fibrillation
Koonlawee Nademanee, MD, FACC, Mark C. Schwab, MD, Erol M. Kosar, MD, FACC,
Margaret Karwecki, NP, Michael D. Moran, MD, FACC, Nithi Visessook, MD,
Anthony Don Michael, MD, FACC, Tachapong Ngarmukos, MD
Inglewood, California
Objectives The purpose of this study was to determine the long-term clinical outcomes of catheter ablation of atrial fibrilla-
tion (AF) substrate for high-risk patients with AF.
Background The benefits of catheter ablation for high-risk AF patients with respect to mortality and stroke reductions remain
unclear.
Methods We performed AF substrate ablation guided by complex fractionated atrial electrogram (CFAE) mapping in 674
high-risk AF patients. The clinical end points were sinus rhythm (SR), death, stroke, or bleeding. Of these 674
patients, 635 were available for follow-up and made up the study cohort. The patients were relatively old (mean
age 67  12 years) and 129 had an ejection fraction (EF) 40%.
Results After the mean follow-up period of 836  605 days, 517 were in SR (81.4%). There were 15 deaths among the
patients who stayed in SR compared with 14 deaths among those who remained in AF (5-year survival rate,
92% vs. 64%, respectively; p  0.0001). SR was the most important independent favorable parameter for sur-
vival (hazard ratio 0.14, 95% confidence interval 0.06 to 0.36, p  0.0001), whereas old age was unfavorable.
Warfarin therapy was discontinued in 434 of the 517 patients in SR post-ablation (84%) whose annual stroke
rate was only 0.4% compared with 2% in those with continuing warfarin treatment (p  0.004).
Conclusions CFAE-targeted ablation of AF is effective in maintaining SR in selected high-risk AF patients and might allow pa-
tients to stop warfarin therapy. SR after AF ablation is a marker of relatively low mortality and stroke risk. Our
findings support conducting further randomized studies to determine whether AF ablation is associated with
mortality and/or stroke reduction. (J Am Coll Cardiol 2008;51:843–9) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.044i
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aespite advances in cardiovascular therapeutics in recent
ears, management of AF remains a frustrating dilemma for
hysicians. Since the publication of the AFFIRM (Atrial
ibrillation Follow-up Investigation of Rhythm Manage-
ent) study and several other randomized trials, which
ompared 2 strategies of AF treatment (rate vs. rhythm
ontrol), most arrhythmia scholars have acknowledged that
n addition to anticoagulation the use of antiarrhythmic
rugs to maintain sinus rhythm (SR) adds no benefit to
eduction in mortality or stroke in AF patients when
ompared with the use of drugs for rate control (1–4).
owever, although recognizing that rate-control treatment
rom the Pacific Rim Electrophysiology Research Institution, Inglewood, California.
r. Nademanee has received a research grant from Biosense Webster Inc. and
onorarium from both Biosense Webster and St. Jude Medical.c
Manuscript received August 22, 2007; revised manuscript received October 10,
007, accepted October 29, 2007.s an acceptable pharmacologic approach, many physicians
re unsatisfied with having their high-risk patients remain
n AF. Subsequent analysis of the AFFIRM data suggests
hat the unwanted effects of antiarrhythmic drugs might
ffset the benefits of being in SR (5). Naturally, this
iscontentment with the pharmacologic approach is the
ajor step leading to the development of nonpharmacologic
reatment approaches to AF.
Over the past decade, catheter ablation has emerged as a
romising approach for treating AF (6–12). However, most
F ablation studies had a short-term follow-up period and
ncompassed a relatively young patient population, unlike
he patient population reported in the AFFIRM trial. As a
esult, most physicians often ask the key question: will
atients who are maintained in SR by catheter ablation have
better outcome than those treated conventionally, espe-
ially with respect to the end points of death and/or stroke?
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Catheter Ablation for High-Risk AF Patients February 26, 2008:843–9We recently described a new
approach to AF ablation, which
identifies the target “substrate”
sites with electroanatomic map-
ping of complex fractionated atrial
electrogram (CFAE) (12). Our
technique achieved a high rate of
success in maintaining SR in both
paroxysmal and chronic (persistent
or permanent) AF patients. We
report our findings in this observa-
tional study designed to determine
the long-term outcomes of high-
risk AF patients, including stroke
and mortality rates after catheter
ablation of AF.
Methods
Study population. Our study
ohort consisted of patients who were at least 65 years old or
ad at least 1 or more risk factors for stroke, including
ypertension, diabetes, structural heart diseases, a prior
istory of stroke, transient ischemic attack (TIA), conges-
ive heart failure (CHF), or an ejection fraction (EF) of
40%. We excluded patients with chronic alcoholism,
yocardial infarction within 1 month of the study, terminal
isease, and patients with documented left atrial thrombus.
ll patients signed an informed consent that was approved
y the Institutional Review Board.
apping and ablation of AF. Our AF ablation technique
as been previously described (12). In brief, our patients
nderwent nonfluoroscopic electroanatomical mapping with
he CARTO mapping system (Biosense Webster, Inc.,
iamond Bar, California), after stopping antiarrhythmic
rugs for 5 half-lives or 3 months with amiodarone. The
easons for stopping antiarrhythmic drugs were to avoid the
ossibility that the drugs might have interfered with AF
nduction if the patient presented in SR on the procedural
ate and to avoid the possibility that antiarrhythmic effects
ight have masked any tachycardia that was the initiator of
F in these patients. Heparin (5,000 IU bolus and subse-
uent 1,000 to 1,500 IU bolus to keep the activated clotting
ime 250 s) was used for anticoagulation.
All electroanatomical maps were created for patients who
ere in AF, either spontaneously or by induction. CARTO
rovided a voltage map and enabled the operator to associ-
te areas of CFAE with both atria and coronary sinus. We
sed bipolar recordings filtered at 30 to 500 Hz and defined
he CFAE as follows: 1) fractionated electrograms com-
osed of 2 or more deflections and/or a perturbation of the
aseline with continuous deflection of a prolonged activa-
ion complex; and 2) atrial electrograms with a very short
ycle length (120 ms). The CFAE was tagged and
ssociated with the atrial anatomy created by CARTO,
Abbreviations
and Acronyms
AF  atrial fibrillation
CFAE  complex
fractionated atrial
electrogram
CI  confidence interval
CVA  cerebrovascular
accident
EF  ejection fraction
HR  hazard ratio
INR  international
normalized ratio
RF  radiofrequency
SR  sinus rhythm
TIA  transient ischemic
attackhereby identifying target sites for ablation. tRadiofrequency (RF) applications were delivered with a
aximal temperature of 55°C to 60°C at the catheter tip (4-
nd 8-mm NaviStar catheters [Biosense Webster, Diamond
ar, California]). The 4-mm NaviStar catheter was used
nitially until the 8-mm NaviStar became available in
anuary 2003. We used the 8-mm NaviStar almost exclu-
ively for AF ablation from January 2003 to February 2006.
e stopped using the 8-mm NaviStar and switched to the
rrigated-tip NaviStar catheter, which became available after
ebruary 2006. This report does not include patients whose
F ablations were performed with the irrigated-tip Na-
iStar, because the follow-up period was relatively short.
The primary end points during RF ablation were either
omplete elimination of areas with CFAE or conversion of
F to SR. When areas with CFAE were completely
liminated but the atrial arrhythmias persisted (organized
trial flutter or atrial tachycardia), they were subsequently
apped and ablated (occasionally in conjunction with ibuti-
ide 1 to 2 mg intravenously over 10 to 20 min). If the
rrhythmias were not successfully terminated, external car-
ioversion was performed.
linical end points and assessment of AF recurrences.
he primary end points were restoration and maintenance
f SR, stroke or TIA, major and minor bleeds, systemic
mboli, and all-cause mortality. All patients were followed
n our arrhythmia clinic every 3 months. In this study, we
ased our clinical success of ablation solely on patient
linical symptoms in conjunction with follow-up electrocar-
iogram or event monitor recording and annual Holter
onitoring. Our “blanking period” for arrhythmia recurrent
ssessment was 3 months from the date of the last ablation
rocedure.
chocardiography assessment. A transesophageal echo-
ardiogram was performed to rule out left atrial clot in all
atients who had persistent or permanent AF as well as in
atients with paroxysmal AF who were in AF 48 h before
he procedure. Although left ventricular EF was not a
linical end point, it was available as part of our routine
chocardiographic evaluation both before and after ablation
6 months to 1 year after the ablation) in the majority of our
atients. Independent echocardiographers who were not
nvolved in the study performed the EF assessment.
nticoagulation management. Patients were treated with
arfarin to maintain an international normalized ratio
INR) between 2 and 3 for at least 3 weeks before the
blation as well as after the ablation. Warfarin was discon-
inued 4 days before the ablation. Patients with persistent or
ermanent AF were given enoxaparin sodium 1 mg/kg
ubcutaneously every 12 h before the ablation. Both warfa-
in and enoxaparin were restarted immediately after the
rocedure, but enoxaparin was discontinued 3 days
fterwards.
If the patient remained in SR 3 months after the ablation,
arfarin was then discontinued and aspirin or clopidogrel or
oth were arbitrarily and immediately prescribed for anti-
hrombotic treatment. We also stopped warfarin treatment
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February 26, 2008:843–9 Catheter Ablation for High-Risk AF Patientsmonths after established SR in patients who developed
arly recurrent AF/atrial tachyarrhythmia episodes during
he “blanking period” but reverted to SR afterwards.
Patients who developed recurrent AF were restarted on
arfarin if their clinical recurrent AF episodes lasted longer
han 12 h. The rationale for using a 12-h duration of AF as
cut-off to resume warfarin treatment was based on our
reliminary studies involving AF patients who had catheter
blation and implantable devices (implantable cardioverter-
efibrillator or pacemaker) (13).
tatistical and data analysis. Baseline characteristics of
atients were compared with t tests and chi-square tests.
he primary analysis was comparison of mortality and
troke rates from the last ablation procedure; patient mor-
ality, stroke probabilities, and standard error were esti-
ated with the Kaplan-Meier method and tested by log-
ank test. Secondary analyses were conducted to compare
he results among different specific subgroups and adjusting
ofactors, including SR, congestive heart failure (CHF),
ypertension, EF 40%, and female gender. A Cox pro-
ortional hazards survival model with stepwise procedure
as used to evaluate the effect of these covariates (14).
isher exact tests were used to analyze the associations of
he AF ablation in maintaining SR with various categorical
actors (type of AF, left atrial size 50 mm, EF 40%, AF
uration 2 years, and age 75 years). Their multivariate
elationships were evaluated with multinomial logistic
egression.
esults
he enrollment period was from March 2000 to February
006; the last cut-off date for the follow-up period was May
aseline Clinical Characteristics of Study Patients
Table 1 Baseline Clinical Characteristics of Study Patients
Total number of patients 635
Age (yrs) 67 12 (median  69)
75 yrs (n) 169 (26.6%)
Female (n) 212 (33.4%)
Type of AF (n)
Paroxysmal 254 (40%)
Persistent 146 (23%)
Permanent 235 (37%)
Risk factors (n)
Hypertension 308 (48.5%)
Previous stroke 61 (10%)
Heart failure 73 (12%)
Coronary disease 131 (21%)
Cardiomyopathy 70 (11%)
Valvular disease 106 (17%)
Diabetes 75 (12%)
AF duration (months) 40 62
Average EF % (n  565) 50 13
EF 40% (n) 129 (22.8%)
LA size (mm) 45 6
Previous antiarrhythmics 2.6 0.8cF  atrial fibrillation; EF  ejection fraction; LA  left atrial.1, 2007. During this period, we evaluated 2,356 patients
ith symptomatic refractory AF; 771 patients met our
nclusion criteria, all having a high risk of stroke and similar
o those patients studied in the AFFIRM trial. Of these 771
atients, 674 underwent a catheter ablation for AF. Of the
7 patients who were not treated, 27 were excluded because
f a left atrial thrombus, and the other 70 patients declined
he procedure.
Table 1 summarizes the clinical characteristics of our
tudy cohort, which consisted of 635 of the 674 patients
ho underwent AF ablation and were followed in our
rrhythmia clinic. The other 39 patients who had only 1
blation and did not have a follow-up period beyond 3
onths after the ablation were not included in statistical
nalysis, because they fell in the “blanking period” (3
onths after the ablation) of the recurrent arrhythmia
ssessment and could not be categorized as to whether the
blations in these patients were effective and in the SR
roup or ineffective and in the AF group.
A total of 1,065 ablations were performed on the 635
atients: 329 patients (52%) underwent 1 procedure, 204
32%) required 2 procedures, 80 (12.6%) required the
rocedure 3 times, and only 22 patients (3.5%) required 4
rocedures.
aintaining SR after ablation. After a mean follow-up
eriod of 836  605 days from the last ablation procedure,
17 of the 635 remained in SR (81.4%); the remaining 118
atients (18.6%) continued to have atrial tachyarrhythmias
paroxysmal AF in 25 patients, persistent AF in 24, perma-
ent AF in 53, and atypical atrial flutter in 16 patients). Of
he 517 patients who remained in SR, only 68 patients
13%) required antiarrhythmic agents to maintain SR (48
miodarone, 19 sotalol, and 1 dofetilide).
As shown in Table 2, AF ablations are significantly more
ffective in maintaining SR in patients with paroxysmal AF
89%; 226 of 254 patients) and persistent AF (85%; 124 of
46 patients) compared with those with permanent AF
71%; 167 of 235 patients). Longer AF duration and larger
eft atrial size lowered the success rate of maintaining SR.
nivariate and multivariate analysis of discrete variables
omparison of Baseline Clinical Characteristics ofatients Maintaining SR Versus Patients Remainingn AF After Abl tio
Table 2
Comparison of Baseline Clinical Characteristics of
Patients Maintaining SR Versus Patients Remaining
in AF After Ablation
SR
(n  517)
AF
(n  118) p Value
Age (yrs) 67 12 67 12 0.9
AF duration (months) 36 57 57 79 0.008
Ejection fraction (%) 51 14 51 12 0.97
LA size (mm) 45 6 48 7 0.0001
Type of AF
Paroxysmal (n  254) 226 28
Persistent (n  146) 124 22 0.0001
Permanent (n  235) 167 68
F  atrial fibrillation; LA  left atrial; SR  sinus rhythm.learly demonstrated that AF duration 2 years and left
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Catheter Ablation for High-Risk AF Patients February 26, 2008:843–9trial size 50 mm were negative predictors of maintaining
R (p  0.01), whereas EF 40% had no impact on the
ong-term success of maintaining SR in our patient popu-
ation (p  0.69).
ffects of sinus rhythm on mortality. Over the follow-up
eriod, there were 29 deaths (Table 3); 15 of the 517
atients who remained in SR died (3%; 4 from CHF, 1
udden death, and 10 noncardiac deaths), compared with 14
f 118 patients with recurrent AF who died (12%; 8 from
HF, 2 sudden deaths, 2 noncardiac deaths, and 2 from
troke including 1 patient with a spontaneous intracranial
emorrhage while taking warfarin). Clearly, the cardiac
eath rate was much lower in patients who stayed in SR
nderlying Diseases and Causesf D ath of Individual Patient Who Died
Table 3 Underlying Diseases and Causesof Death of Individual Patients Who Died
Patient #
Age
(Gender)
Underlying
Disease(s)
Final
Rhythm
Cause of
Death
Follow-Up
(Days)
1 55 (F) Mitral valvular
disease
(valve
replacement)
AF SD 1,140
2 83 (M) HTN AF SD 791
3 73 (M) CAD & HTN AF Renal failure 291
4 82 (M) HTN AF Prostate cancer 1,744
5 77 (M) CAD AF Intracranial
hemorrhage
1,565
6 64 (M) HTN AF Stroke 194
7 73 (M) CAD & DM AF CHF 855
8 86 (M) CAD AF CHF 724
9 78 (M) CAD & CHF AF CHF 582
10 89 (M) CAD & CHF AF CHF 408
11 70 (M) CAD & valve
replacement
AF CHF 409
12 77 (F) HTN & stroke AF CHF 582
13 83 (F) CAD & CHF AF CHF 596
14 68 (M) CAD & CHF AF CHF 518
15 88 (M) CAD & HTN SR SD 567
16 85 (F) HTN & CHF SR Pneumonia 1,201
17 80 (M) HTN & CHF SR Cancer 2,041
18 62 (F) Cardiomyopathy
& CHF
SR Ruptured
bowels
898
19 84 (F) HTN SR Pancreatic
cancer
1,274
20 72 (M) CAD & COPD SR Respiratory
failure
729
21 75 (F) CHF & COPD SR Respiratory
failure
865
22 78 (F) HTN & DM SR Pneumonia 1,070
23 86 (F) HTN SR Sepsis 1,103
24 79 (F) CAD & CHF SR Pulmonary
emboli?
1,805
25 88 (M) HTN SR Prostate cancer 567
26 75 (M) CAD & CHF SR CHF 489
27 52 (M) Cardiomyopathy SR CHF 566
28 79 (M) HTN & CHF SR CHF 512
29 75 (M) CHF & COPD SR CHF 408
AD  coronary artery disease; CHF  congestive heart failure; COPD  chronic obstructive
ulmonary disease; DM  diabetes mellitus; HTN  hypertension; SD  sudden death; other
bbreviations as in Table 2.0.96% vs. 8%; p  0.0001). CPatients whose AF ablation was effective in maintaining
R had a much lower 5-year mortality rate (8%) when
ompared with a 36% 5-year mortality rate in those with
ecurrent AF after the ablation (Fig. 1) (p  0.0001). The
azard ratios (HRs) for death for SR, history of CHF, EF
40%, hypertension, and female gender are shown in Table
. The SR was the strongest independent factor associated
ith a lower mortality (HR 0.14, 95% confidence interval
CI] 0.06 to 0.36, p  0.0001). Age is an independent
redictor of mortality (HR 1.06, 95% CI 1.02 to 1.11, p 
.004), whereas other factors such as EF, CHF, and
ypertension were not independently associated with an
ncrease in mortality in this patient population.
Figure 2 clearly shows that patients in AF who had an EF
40% had the worst prognosis. More importantly, patients
hose EF was 40% but remained in AF had a higher
ortality rate compared with patients in SR regardless of
heir EF.
ffects of maintaining SR on EF. Of the 129 patients
ith an EF 40%, 102 maintained SR (79%). After 6
onths of SR, the EF was significantly improved (Fig. 3);
he EF increased from 31  7% to 41  13% (p  0.001).
n contrast, there were no changes in EF in the 27 patients
ho failed to respond to AF ablations and remained in AF
before ablation EF was 24  8% and after ablation EF was
3.5  9%).
Figure 1 Effects of Maintaining NSR
After AF Ablation on Survival
Kaplan-Meier curve demonstrating improved survival in patients who remained
in normal sinus rhythm (NSR) (red circles) from all-cause mortality compared
with patients who remained in atrial fibrillation (AF) (green circles).
ultivariate Cox Regression Analysisf Haz d Rati of Key Risk Vari ble
Table 4 Multivariate Cox Regression Analysisof Hazard Ratio of Key Risk Variables
Hazard
Ratio 95% Confidence Interval p Value
Sinus rhythm 0.14 0.058–0.36 0.0001
CHF 2.5 0.93–6.69 0.068
Age 1.06 1.02–1.11 0.004
EF 40% 0.982 0.949–1.016 0.298
LA size (50 mm) 1.068 0.99–1.15 0.08
Hypertension 1.77 0.78–4.03 0.17
Female 1.079 0.45–2.58 0.86HF  congestive heart failure; EF  ejection fraction; LA  left atrial.
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February 26, 2008:843–9 Catheter Ablation for High-Risk AF Patientselation between discontinuation of anticoagulation
herapy, bleeding, stroke, and embolic incidence. War-
arin therapy was discontinued in 434 of the 517 patients
ho remained in SR (84%). Eleven patients experienced a
ajor stroke or TIA. In the patients who discontinued
arfarin, 5 patients had a cerebrovascular accident (CVA)
3 ischemic strokes and 2 TIAs); 4 patients had no recurrent
ymptomatic AF. One patient who had TIA reported
ymptoms of palpitations before the central nervous system
vent, but he was in SR at the time of the hospital visit.
In comparison, 6 patients in the AF group who required
arfarin (4 had adequate INR within 3 months before the
vent, but in 2 patients, no INR was available within 3
onths of the event) had CVAs (5 ischemic strokes and 1
atal intracranial hemorrhage). Figure 4 shows the 5-year
troke rate was 3% in the patients who had stopped taking
arfarin compared with 23% in the patients who remained
n AF and continued taking warfarin (p  0.004).
rocedure complications. Five patients suffered a CVA
0.8%); 2 of the CVAs occurred 24 to 48 h after the
rocedure. Hemopericardium occurred in 9 patients (1.4%);
 required a surgical repair, owing to perforation of the left
Figure 2 Effects of NSR After AF Ablation and EF on Survival
Multiple overlay Kaplan-Meier survival curves among 4 strata of patients: 1)
patients with ejection fraction (EF) 40% and NSR (red circles); 2) patients
with EF 40% and SR (green circles); 3) patients with EF 40% and AF (pur-
ple circles); and 4) patients with EF 40% and AF (blue circles). Abbreviations
as in Figure 1.
Figure 3 Beneficial Effect of NSR After AF
Ablation on Left Ventricular Function
Comparison of individual changes of EF before and after ablation. Pre  before
ablation; Post  6 to 12 months after ablation. Abbreviations as in Figure 1.ptrium. The remaining 6 patients were treated uneventfully
ith pericardiocentesis. Thirteen patients developed vascu-
ar complications at the femoral puncture site (7 pseudo-
neurysms, 2 arteriovenous fistulas, and 4 with severe
leeding [including 1 patient with retroperitoneal bleeding]
t the groin site, which required a blood transfusion). Two
atients developed high-grade atrioventricular nodal block
equiring permanent pacemaker implantation. Three patients
eveloped transient pulmonary edema after the procedure,
hich resolved with diuretic therapy. We observed no serious
rocedure-related late complications, such as esophageal-left
trial fistula or clinical pulmonary vein stenosis.
No procedurally related deaths occurred; however, 2
atients died within 30 days after the procedure. One of the
atients had a CVA within 48 h of the procedure and
ventually died weeks later. The other patient died from
espiratory failure due to complications of chronic obstruc-
ive pulmonary disease and pneumonia.
iscussion
ur study is the first to systematically evaluate the safety
nd effectiveness of catheter-based substrate ablation in a
igh-risk AF patient population with an extended long-
erm follow-up period. Our patients were much older
median age, 69 years) than those reported in other studies
nvolving catheter ablation treatment of AF.
Despite this high-risk profile, our data support the fact
hat AF substrate ablation guided by CFAE mapping is
ffective in maintaining SR. At 2.3-year mean follow-up,
atients who had the highest success rates (89% and 85%,
espectively) were those whose presenting rhythm was
aroxysmal or persistent AF compared with 71% of those
ith permanent AF (p  0.0001).
A key question regarding maintenance of SR after cath-
ter ablation in our study is inevitably raised: how does one
ule out occurrences of asymptomatic AF episodes? And if
here are asymptomatic AF episodes, what are the risks of
troke and embolic complications if the patients are not
Figure 4 Comparison of Stroke-Free
Survival: Warfarin vs. No Warfarin
Red circles  no warfarin sodium; green circles  warfarin sodium.rotected by anticoagulation?
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Catheter Ablation for High-Risk AF Patients February 26, 2008:843–9However, our stroke and embolic complication rates are
ow, despite the majority of our patients who remained in
R stopping their anticoagulation. The annual stroke rate in
ur successfully treated patients who discontinued antico-
gulation was only 0.4% compared with 2% (both ischemic
nd nonischemic) in the patients with recurrent AF who
equired warfarin. The Kaplan-Meier–derived 5-year stroke
ncidence was only 3% compared with 23% for patients who
equired ongoing warfarin therapy (p  0.04).
Although the reasons for the lower stroke rate in our
atient population are unclear, several possible explanations
ould have contributed to this observation in our study: 1)
ur patients who have had successful AF ablation continue
o maintain SR at a much better rate than that seen in the
harmacologic treatment and possibly have a much less
requent and/or shorter duration of asymptomatic AF epi-
odes; and 2) continuance of SR promotes atrial remodeling
hat is less conducive to thrombus formation (15). Although
his reasoning is merely speculative, our observation shows
hat once SR is restored and maintained by catheter sub-
trate ablation, the risk of stroke decreases.
Undoubtedly, the preceding data will generate future
ebate over the requirements for continued anticoagulation
n patients after successful AF ablation. Oral et al. (16)
ecently reported data from their laboratory demonstrating
hat the stroke rate in their patients was quite low after
uccessful RF ablation. Our data not only support their
ndings but also extend these benefits to a higher-risk
atient population, particularly the very elderly. Random-
zed trials are warranted to substantiate and confirm the
receding findings.
Meanwhile, our data suggest that AF substrate ablation
ight represent a viable treatment modality for high-risk
F patients who either have a contraindication to antico-
gulation or cannot reliably adhere to the rigorous moni-
oring protocol. Whether physicians will embrace the ther-
peutic goal of stopping anticoagulation as a benefit of AF,
blative treatment is likely to remain controversial. How-
ver, there are more benefits from being in SR after AF
blation than just a reduction in stroke rate.
Our data also showed a better 5-year survival rate in
atients who maintained SR (Fig. 3) than in those who
emained in AF (92% vs. 64%; p  0.0001). It is possible
hat patients whose AF ablation failed to restore SR had
ore advanced heart disease or unrecognized risk factors
hat could have prevented them from maintaining SR and
nfavorably influenced their overall survival as well. However,
ith the exception of the left atrial size and duration of AF,
hich are greater in patients who did not respond to AF
blation (Table 2), there were no differences in terms of
aseline patient characteristics including EF. Multivariate
nalysis and Cox regression analysis convincingly show SR as
n independent predictor of a favorable prognosis, whereas EF,
ypertension, and female gender had little effect (Table 3).
Patients who maintained SR regardless of the baseline
F had a lower mortality rate than their counterparts on the (ame corresponding EF stratum (Fig. 2). One reason that
atients who had a lower EF (40%) but maintained SR
ared better is the significant recovery of their ventricular
unction after restoring SR. The average EF increased from
mean of 31% before ablation to 41% after successful
blation (p  0.001). In contrast, patients who had recur-
ent AF after ablation had no change in their EF.
Our data dovetail nicely with the findings of Hsu et al.
17) and Gentlesk et al. (18), that many AF patients with a
epressed baseline EF show improvement in their EF after
R has been restored with a successful AF ablation. It is also
lausible that the improved LV function after maintaining
R in our patients with prior depressed EF resulted in
mproved survival. Indeed, our data suggest that this might
e the case, because the significant reduction in cardiac
eath, especially from CHF, is quite evident in our study; 4
f 517 patients (0.8%) who stayed in SR died from CHF
ompared with 8 of 118 (6.7%) patients who remained in
F (p  0.0001).
tudy limitations. Our study is not a randomized trial and
oes not have a control group receiving conventional treat-
ent for AF. One could criticize the possibility of selection
ias in our study patients. For example, one might question
hether our patient population is less ill than those observed
n the AFFIRM study. We believe that this is not the case,
ecause our patient selection criteria are the same as in the
FFIRM study. Furthermore, the median age of our
atient population is comparable to that observed in the
FFIRM trial.
More importantly, the benefit of our patients being in SR
as apparent with respect to mortality, stroke reduction,
nd improved LV function. In addition, there are no
tatistically significant differences in baseline population
haracteristics between patients who maintained SR after
blation and those who remained in AF, with the exception
f larger left atrial size and longer AF duration in the latter
roup. Also, patients with permanent AF had a higher
ailure rate compared with patients with paroxysmal AF.
till, multivariate analysis clearly shows SR as an indepen-
ent factor for favorable prognosis, emphasizing that the
onsequences of AF are unfavorable to long-term survival
nd cardiac function.
One might also question stopping warfarin treatment
ithout rigorous monitoring of asymptomatic AF episodes.
lotzer et al. (19) reported data from the MOST (MOde
election Trial), which showed that patients with sick sinus
yndrome and permanent pacemaker implantation, who had
igh atrial event rates (5 min), had higher mortality and
onfatal stroke rates. However, Capucci et al. (20) reported
ifferent findings in a cohort of patients with bradycardia
nd AF who received DDDR pacemakers (AT500,
edtronic Inc., Minneapolis, Minnesota). They found that
he incidence of stroke and arterial embolism is quite low in
atients whose AF duration is 24 h. The reason for
onflicting findings between these 2 studies remains unclear
both have similar patient populations and median age of
t
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February 26, 2008:843–9 Catheter Ablation for High-Risk AF Patientshe study patients). However, their patient populations are
learly different than our patient population, because all our
atients had undergone AF ablation.
It is possible that the asymptomatic atrial tachyarrhyth-
ias, which occurred after AF ablation in our study, were
ifferent than those observed in the MOST study. It is
lausible that patients with a high rate of atrial events in the
OST study eventually developed persistent or longer
pisodes of AF (1 day)—as suggested in their data—and
n turn further increased risk of stroke substantially, whereas
ur asymptomatic atrial tachyarrhythmia episodes did not
urther degenerate to persistent AF because of the effect of
he AF ablations.
One might speculate that the majority of our patients
ho developed recurrent atrial tachyarrhythmia episodes
fter ablation became symptomatic and therefore were
dentified and treated with warfarin. In any event, the stroke
ate in our patients who maintained SR is very low, with a
-year stroke rate of only 3%, suggesting that, if any
symptomatic AF episodes occurred in these patients, they
ere inconsequential.
linical implications. Our data demonstrate that catheter
ubstrate ablation of AF guided by CFAE mapping is
ffective in maintaining SR in high-risk AF patients and
hat this effect is long-lasting. The benefits of being in SR
n our patient population are remarkable with respect to
troke and mortality reduction. These findings might have
n impact on our management of high-risk AF patients,
specially in elderly patients, who are not always ideal
andidates for anticoagulation (21).
The benefits of AF substrate ablation have to be balanced
gainst the potential complications of the procedure. Al-
hough the procedure-related stroke rate of 0.8% is relatively
ow, it remains concerning. The recent introduction of an
rrigated-tip ablation catheter might represent a major
dvance in reducing the risk of peri-procedural embolic
omplications. If successful in reducing peri-procedural
VA, it will likely replace the 4- and 8-mm nonirrigated tip
blation catheters that were used in our study. A significant
umber of our patients had multiple ablative sessions, and
his unavoidably poses incremental risk to such patients.
ikewise, cardiac tamponade is a small but serious risk that
equires continuous attention and preparation to promptly
ecognize and treat these patients.
Our report from a single center clearly suggests that
aintaining SR by catheter substrate ablation is a marker of
elatively low mortality and stroke risk. Our findings support
hat further randomized controlled studies are merited to
etermine whether AF ablation is associated with a mortality
nd stroke reduction in a high-risk AF patient population.
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